• Home  /
  • Healthcare   /
  • Noticeable Buzzers: Exact Sciences Corporation (EXAS) ,Cerus Corporation (CERS)

Noticeable Buzzers: Exact Sciences Corporation (EXAS) ,Cerus Corporation (CERS)

Exact Sciences Corporation (EXAS) , a stock from Medical Laboratories & Research Industry, has a value of $34.70 per share, noted a price change of -5.17% in recent trade close. The P/S ratio is 28.98.  The performance for one month is at 1.20% and the performance for half year is 149.64%. The performance for recent week is -4.85% and the performance for three months is at 58.16%. The performance for Year to Date (YTD) is 159.73%. Its monthly volatility value of 4.63% and volatility for the week is valued at 4.82%.

93.30% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of 3.04% in last three month period. Insiders own 1.70% of the company shares. During last six month record, the net percent change kept by insiders has observed a change of -3.56%. The Stock has P/B of 12.39. The price-to-book ratio is a ratio used to compare a stock’s market value to its book value. It is calculated by dividing the current closing price of the stock by the latest quarter’s book value per share.

A ROI of -49.60% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments. Analysts mean Recommendation on a stock is scored at 1.80. Demonstrating how profitable this stock is relative to its assets, the ROA value is noted at -43.60%. The ROA tells us exactly what earnings were made from the invested capital. The company is expecting to attain earnings per share (EPS) growth of 4.60% in this year and the earnings per share (EPS) growth estimated to be 32.60% in the next year. Annual earnings per share (EPS) growth was at -24.50% in past 5 Years and Long-term annual earnings per share (EPS) growth is projected to achieve 67.93% in coming 5 years.

U.S. markets fell for the second consecutive day on geopolitical concerns. Inventors appear to be cautious ahead of upcoming events such as the U.K. general election, testimony by former FBI director James Comey and a policy meeting of the European Central Bank, all of which are plannedfor Thursday. The Dow Jones Industrial Average declined 0.23 percent to close at 21,136.23, while the S&P 500 Index dipped 0.28 percent to close at 2,429.33.

 

“We expect sideways markets over the short-term due to seasonality—summer months tend to be quieter—and investors continue to react to headline news,” stated Lisa Kopp, head of Traditional Investments Group at U.S. Bank Wealth Management.

Cerus Corporation (CERS) has a value of $2.62 per share, noted a price change of 11.49% in last trade session. The performance for month is -15.76% and the performance for half year is -47.70%. Indicating how profitable this stock is relative to its assets, the ROA value is observed at -60.80%. The ROA tells us exactly what earnings were generated from the invested capital. A ROI of -79.90% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.

The P/S ratio is 6.71. The low P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback.  69.60% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of -2.09% in last three month period. Insiders own 1.70% of the company shares. During last six month record, the net percent change kept by insiders has observed a change of -0.96%.

Annual earnings per share (EPS) growth noted at -11.80% in past 5 Years . The company is estimating to achieve earnings per share (EPS) growth of -6.20% in this year and the earnings per share (EPS) growth expected to be 23.40% in the next year. Stock has P/B of 6.55. A lower P/B ratio could mean that the stock is undervalued. However, it could also mean that something is fundamentally wrong with the company. As with most ratios, be aware that this varies by industry.

The performance for week is 14.41% and the performance for quarter is at -32.99%. Its monthly volatility value of 7.54% and volatility for the week is valued at 6.05%. The performance for Year to Date (YTD) is -39.77%.Analysts mean Recommendation on a stock is noted at 1.30. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.

Cerus Corporation (CERS) reported  that the predictable Fresenius Kabi platelet additive solution (PAS) shortage the firmreported on May 23, 2017, could be less disruptive to blood center production of INTERCEPT platelets than initially anticipated.

This follows a decision by the FDA to review a recent submission by Fresenius Kabi as a Changes Being Effected in 30 Days (CBE-30) supplement, which allows ongoing distribution of the product during the review period. The CBE-30 was necessary to address some changes in raw materials used by the manufacturer of the PAS container.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment